Pulmocide

Respira

This biopharmaceutical company develops inhaled drug-device therapies for patients with cardiopulmonary diseases such as pulmonary hypertension and interstitial lung disease.

F2G

This biopharmaceutical company develops novel antifungal therapies to treat patients with life-threatening rare and resistant fungal infections.

Aer Therapeutics

This biopharmaceutical company develops inhaled mucolytic treatments for patients with muco-obstructive lung diseases, including chronic obstructive pulmonary disease and asthma.

Breath Therapeutics

This biopharmaceutical company develops inhaled drug-aerosol therapies for patients with bronchiolitis obliterans syndrome and other severe respiratory diseases.

Viamet Pharmaceuticals

This company develops small molecule antifungal medicines for patients with chronic and life-threatening infections using a proprietary metalloenzyme inhibitor design platform.

Kinaset Therapeutics

This biopharmaceutical company develops inhaled anti-inflammatory therapies to treat patients with severe asthma and other respiratory diseases.

AQUILON PHARMACEUTICALS

The company develops inhaled medicines and nasal sprays for patients with asthma, chronic obstructive pulmonary disease and other respiratory conditions.

Melinta Therapeutics

This biopharmaceutical company develops and commercialises antibiotics and antifungals to treat drug-resistant infections in hospital and clinic settings.